Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

Rhea-AI Summary

Pharming Group announced that all proposals were approved at its 2025 Annual General Meeting of Shareholders. Key highlights include the appointment of Dr. Elaine Sullivan, an experienced pharmaceutical and biotech industry leader, to the Board of Directors for a four-year term. The company also reelected Mrs. Jabine van der Meijs and Mr. Leonard Kruimer as Non-Executive Directors for four-year terms. Mrs. Deborah Jorn and Mr. Steven Baert did not seek re-election after serving six and four years respectively. Shareholders approved the reappointment of Deloitte Accountants B.V. as external auditor for 2025 and renewed authorizations for the Board to issue and repurchase shares.

Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.

Dr. Elaine Sullivan, a seasoned leader in the international pharmaceutical and biotech industry with deep R&D expertise and public non-executive board experience, was appointed to the Pharming Board of Directors, upon binding recommendation of the Board of Directors, for a period of four years (agenda item 3).

Mrs. Jabine van der Meijs and Mr. Leonard Kruimer were reelected as Non-Executive Directors, upon binding recommendation of the Board of Directors, for a period of four years (agenda items 4.a and 4.b respectively).

After six years of dedicated service to the company, Mrs. Deborah Jorn did not stand for re-election. In addition, Mr. Steven Baert, who served on the Board for four years, did not stand for re-election. On behalf of the Board, Richard Peters, Chairman, expressed his heartfelt gratitude to Deborah and Steven for their services and many valuable contributions.

Shareholders also approved the proposals to reappoint Deloitte Accountants B.V. as the external auditor of the Company for the financial year 2025 (agenda item 5), to renew the authorizations for the Board of Directors to issue shares (agenda item 6) and to repurchase shares (agenda item 7).

A recording of the webcast, presentation slides from today’s AGM, the voting results and more details regarding agenda items are available on the Company’s website under Investors/Shareholder Meetings.

About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Attachment

• Pharming AGM results press release 2025_EN_11JUN25

FAQ

Who is Dr. Elaine Sullivan and what is her new role at Pharming Group (PHAR)?

Dr. Elaine Sullivan is a seasoned leader in the pharmaceutical and biotech industry with extensive R&D expertise who was appointed to Pharming Group's Board of Directors for a four-year term at the 2025 AGM.

What key proposals were approved at Pharming Group's 2025 AGM?

Shareholders approved the appointment of Dr. Elaine Sullivan, reelection of two Non-Executive Directors, reappointment of Deloitte as external auditor, and renewed authorizations for the Board to issue and repurchase shares.

Who stepped down from Pharming Group's Board of Directors in 2025?

Mrs. Deborah Jorn, who served for six years, and Mr. Steven Baert, who served for four years, did not stand for re-election to the Board of Directors.

Which directors were reelected to Pharming Group's Board in 2025?

Mrs. Jabine van der Meijs and Mr. Leonard Kruimer were reelected as Non-Executive Directors for four-year terms.